News for UCB SA (UCBJY)

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

UCB (UCBJY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

UCB (OTC: UCBJY) reports positive Phase 3 trial results for fenfluramine in treating CDKL5 deficiency disorder (CDD). The study successfully met primary

UCB (UCBJY) presents three pioneering research posters on thymidine kinase 2 deficiency (TK2d) at the UMDF Mitochondrial Medicine 2025 Conference. The r

UCB (UCBJY) awarded 15 scholarships as part of the inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship program. The scholarship recipients include ind

Adia Nutrition Inc. invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com WINTE

UCB (UCBJY) and Domino Data Lab have embarked on a strategic collaboration to modernize the Statistical Computing Environment (SCE) for life sciences. T

HSBC analyst Rajesh Kumar has adjusted the price target for UCB (UCBJF), lowering it to EUR 179 from EUR 203, while maintaining a Buy rating on the shares. This

Strong focus on neurology and immunology therapeutic areas.Robust pipeline of innovative drugs and treatments.Risks include regulatory hurdles and competitive

**media[572648]**

European stock markets experienced a downturn, driven by investor concerns over Germany's spending plans, the impact of U.S. economic growth, and tariffs. The S

Revenue Growth: 17% increase, 19% at constant rate, reaching EUR6.150 billion.Net Sales: EUR5.6 billion, 15% growth, 17% at constant rate.Adjusted Gross Margin

Feb 27, 2025 / 01:00PM GMTAntje Witte - Ucb SA - Head of Investor Relations Welcome to the UCB full year 2024 Capital Market Call. My name is Antje. I'm the Hea

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Belgium stocks lower at close of trade; BEL 20 down 0.90%

Belgium stocks higher at close of trade; BEL 20 up 0.43%

Belgium stocks higher at close of trade; BEL 20 up 0.54%

Belgium stocks higher at close of trade; BEL 20 up 0.54%

Belgium stocks lower at close of trade; BEL 20 down 0.64%